MA49809A1 - Composés utilisés comme inhibiteurs de kinase - Google Patents

Composés utilisés comme inhibiteurs de kinase

Info

Publication number
MA49809A1
MA49809A1 MA49809A MA49809A MA49809A1 MA 49809 A1 MA49809 A1 MA 49809A1 MA 49809 A MA49809 A MA 49809A MA 49809 A MA49809 A MA 49809A MA 49809 A1 MA49809 A1 MA 49809A1
Authority
MA
Morocco
Prior art keywords
kinase inhibitors
compounds used
tyrosine kinase
compounds
inhibitors
Prior art date
Application number
MA49809A
Other languages
English (en)
Inventor
Nicolas Guisot
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en
Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of MA49809A1 publication Critical patent/MA49809A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés. Les composés selon l'invention sont des inhibiteurs de tyrosine kinase. De manière spécifique, les composés selon l'invention sont utilisés comme inhibiteurs de la tyrosine kinase de bruton (btk). L'invention concerne également l'utilisation de ces composés pour le traitement d'affections pouvant être traitées en inhibant la tyrosine kinase de bruton, par exemple le cancer, le lymphome, la leucémie et les maladies immunologiques.
MA49809A 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase MA49809A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1522245.8A GB201522245D0 (en) 2015-12-16 2015-12-16 Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en) 2016-08-15 2016-08-15 Compounds useful as kinase inhibitors
PCT/GB2016/053968 WO2017103611A1 (fr) 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase

Publications (1)

Publication Number Publication Date
MA49809A1 true MA49809A1 (fr) 2021-08-31

Family

ID=57590725

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055064A MA55064A (fr) 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase
MA49809A MA49809A1 (fr) 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA055064A MA55064A (fr) 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase

Country Status (36)

Country Link
US (7) US10695323B2 (fr)
EP (2) EP3782994A1 (fr)
JP (3) JP6731483B2 (fr)
KR (2) KR102215792B1 (fr)
CN (9) CN114716381A (fr)
AU (4) AU2016373530B2 (fr)
CA (1) CA3008488C (fr)
CL (1) CL2018001591A1 (fr)
CO (1) CO2018006164A2 (fr)
CR (1) CR20180367A (fr)
CY (1) CY1123561T1 (fr)
DK (1) DK3390395T3 (fr)
EA (1) EA035132B1 (fr)
ES (1) ES2828431T3 (fr)
FI (1) FIC20240004I1 (fr)
FR (1) FR24C1009I1 (fr)
HK (1) HK1263254A1 (fr)
HR (1) HRP20201835T1 (fr)
HU (2) HUE051921T2 (fr)
IL (4) IL285976B2 (fr)
LT (1) LT3390395T (fr)
MA (2) MA55064A (fr)
MD (1) MD3390395T2 (fr)
MX (2) MX2018007267A (fr)
NL (1) NL301262I2 (fr)
NZ (1) NZ743553A (fr)
PE (3) PE20220507A1 (fr)
PH (1) PH12018501268A1 (fr)
PT (1) PT3390395T (fr)
RS (1) RS60982B1 (fr)
SG (2) SG10202012498TA (fr)
SI (1) SI3390395T1 (fr)
TN (1) TN2018000213A1 (fr)
UA (2) UA122258C2 (fr)
WO (1) WO2017103611A1 (fr)
ZA (4) ZA201804137B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
AU2016322063A1 (en) 2015-09-16 2018-04-12 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
CN114716381A (zh) 2015-12-16 2022-07-08 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
RU2020136310A (ru) * 2018-04-06 2022-05-06 ПРАКСИС БАЙОТЕК ЭлЭлСи Ингибиторы atf6 и их применение
CN112119063B (zh) * 2018-05-18 2023-10-17 富士胶片株式会社 3-二氟甲基吡唑化合物的制造方法及3-二氟甲基吡唑-4-羧酸化合物的制造方法以及吡唑烷化合物
CN117281803A (zh) * 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
EP4010333A1 (fr) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
US20220273593A1 (en) * 2019-09-19 2022-09-01 Johann Wolfgang Goethe-Universität Frankfurt am Main Compounds and compositions for treating kidney disease
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
BR112022009716A2 (pt) 2019-12-06 2022-08-09 Loxo Oncology Inc Dosagem de um inibidor de tirosina quinase de bruton
EP4118086A1 (fr) * 2020-03-12 2023-01-18 Fochon Biosciences, Ltd. Composés utiles en tant qu'inhibiteurs de kinase
TWI809489B (zh) 2020-09-10 2023-07-21 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022228302A1 (fr) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Composés carboxamides hétéroaromatiques et leur utilisation
MX2023013443A (es) 2021-05-14 2023-12-12 Loxo Oncology Inc Formas cocristalinas de un inhibidor de la tirosina cinasa de bruton.
IL309427A (en) * 2021-07-01 2024-02-01 Hangzhou Healzen Therapeutics Co Ltd TYROSINE KINASE AND MUTANT DEGRADER, Broughton's composition and application
WO2023284765A1 (fr) * 2021-07-16 2023-01-19 深圳市塔吉瑞生物医药有限公司 Composé pyrazole substitué, composition le contenant et son utilisation
WO2023110970A1 (fr) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Inhibiteurs macrocycliques de btk
WO2023143355A1 (fr) * 2022-01-28 2023-08-03 Hansoh Bio Llc Dérivé d'amide d'azacycle, ses procédés de préparation et ses utilisations médicinales
WO2023174397A1 (fr) * 2022-03-18 2023-09-21 Insilico Medicine Ip Limited Inhibiteurs de kinase inhibitrice de cdc2 spécifique de la tyrosine et de la thréonine associés à une membrane de pyrazole (pkmyt1) et leurs utilisations
CN115894376A (zh) * 2022-12-15 2023-04-04 南京雷正医药科技有限公司 一种芳香族酰胺类化合物、药物组合物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1212327B8 (fr) 1999-09-17 2004-02-25 Abbott GmbH & Co. KG Pyrazolopyrimidines en tant qu'agents therapeutiques
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
EP2201840B1 (fr) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de Bruton
CN101553224A (zh) * 2006-10-06 2009-10-07 艾博特公司 新型咪唑并噻唑和咪唑并唑
EP2089391B1 (fr) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Sonde d'activité de la tyrosine kinase de bruton et son procédé d'utilisation
EP2548558A1 (fr) 2007-03-28 2013-01-23 Pharmacyclics, Inc. Composé hétérocyclique condensé contenant de l'azote comme inhibiteurs de la tyrosine kinase de bruton
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
MX360970B (es) 2008-06-27 2018-11-23 Avila Therapeutics Inc Compuestos de heteroarilo y usos de los mismos.
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
PL2324008T3 (pl) * 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylopirazole jako inhibitory kinazy białkowej
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
MY191929A (en) 2010-06-03 2022-07-18 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
CA2803292C (fr) 2010-06-30 2016-06-14 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc
HUE033019T2 (en) 2011-05-17 2017-11-28 Principia Biopharma Inc Tyrosine kinase inhibitors
ES2770550T3 (es) 2011-05-17 2020-07-02 Univ California Inhibidores de quinasa
WO2013010136A2 (fr) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton
EP2548877A1 (fr) 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
ES2776175T3 (es) 2012-06-18 2020-08-14 Principia Biopharma Inc Pirrolo- o pirazolopirimidinas covalentes reversibles útiles para el tratamiento de cáncer y enfermedades autoinmunes
US9572811B2 (en) 2012-08-03 2017-02-21 Principia Biopharma Inc. Treatment of dry eye
AU2013299557B2 (en) * 2012-08-10 2017-06-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
CA2888960C (fr) * 2012-11-02 2017-08-15 Pfizer Inc. Inhibiteurs de la tyrosine kinase de bruton
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
KR102272792B1 (ko) 2013-09-30 2021-07-05 광저우 이노케어 파마 테크 씨오., 엘티디. Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도
WO2015075051A1 (fr) * 2013-11-19 2015-05-28 Universitaet Des Saarlandes Inhibiteurs allostériques de protéines kinases c atypiques
US9637486B2 (en) 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
ES2841248T3 (es) 2014-02-21 2021-07-07 Principia Biopharma Inc Sales y forma sólida de un inhibidor de BTK
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CA2974853C (fr) 2015-01-28 2023-02-21 Bayer Pharma Aktiengesellschaft Derives de 4h-pyrrolo[3,2-c]pyridin-4-one
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2016322063A1 (en) 2015-09-16 2018-04-12 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
HUE056877T2 (hu) 2015-12-16 2022-03-28 Boehringer Ingelheim Int Autoimmun betegségek kezelésére alkalmas bipirazolil-származékok
MX2018007422A (es) 2015-12-16 2018-08-15 Ecolab Usa Inc Composiciones de acido peroxiformico para limpieza por filtracion en membrana.
CN114716381A (zh) 2015-12-16 2022-07-08 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
JP6948322B2 (ja) 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン
BR112018012244B1 (pt) 2015-12-16 2022-02-01 Priostar Pty Ltd Formulação, método para controlar uma praga, e, uso

Also Published As

Publication number Publication date
CL2018001591A1 (es) 2018-09-28
EA201891268A1 (ru) 2018-11-30
JP2022120013A (ja) 2022-08-17
AU2021225162B2 (en) 2023-08-03
CN108473481B (zh) 2022-04-19
CN114605327A (zh) 2022-06-10
IL259923A (en) 2018-07-31
US20190000806A1 (en) 2019-01-03
FR24C1009I1 (fr) 2024-05-24
WO2017103611A1 (fr) 2017-06-22
BR112018012341A2 (pt) 2018-12-04
PE20220502A1 (es) 2022-04-07
MX2018007267A (es) 2018-11-09
IL281067A (en) 2021-04-29
MX2021003478A (es) 2022-07-25
JP2018538307A (ja) 2018-12-27
IL281067B (en) 2022-04-01
UA122258C2 (uk) 2020-10-12
PE20181449A1 (es) 2018-09-12
SI3390395T1 (sl) 2020-11-30
PT3390395T (pt) 2020-11-03
US10695323B2 (en) 2020-06-30
US10918622B2 (en) 2021-02-16
CN113636978A (zh) 2021-11-12
PE20220507A1 (es) 2022-04-07
ZA202100544B (en) 2023-06-28
IL259923B (en) 2020-08-31
CY1123561T1 (el) 2022-03-24
MA55064A (fr) 2021-09-29
UA127863C2 (uk) 2024-01-31
AU2021225161A1 (en) 2021-09-30
LT3390395T (lt) 2020-11-25
IL276283B (en) 2021-03-25
HUS2400003I1 (hu) 2024-03-28
CR20180367A (es) 2018-11-12
JP7419437B2 (ja) 2024-01-22
CN113603645A (zh) 2021-11-05
US11826351B2 (en) 2023-11-28
SG10202012498TA (en) 2021-01-28
EA035132B1 (ru) 2020-04-30
JP6731483B2 (ja) 2020-07-29
HUE051921T2 (hu) 2021-03-29
NZ743553A (en) 2022-08-26
ZA202107471B (en) 2023-03-29
CN114716381A (zh) 2022-07-08
HRP20201835T1 (hr) 2021-01-08
DK3390395T3 (da) 2020-09-28
US20200276162A1 (en) 2020-09-03
AU2021201811B2 (en) 2022-01-27
US20190135762A1 (en) 2019-05-09
EP3390395A1 (fr) 2018-10-24
EP3782994A1 (fr) 2021-02-24
AU2021225161B2 (en) 2023-08-03
IL285976B2 (en) 2023-10-01
IL276283A (en) 2020-09-30
AU2021201811A1 (en) 2021-04-22
AU2016373530A1 (en) 2018-07-05
CA3008488C (fr) 2023-10-10
KR20180115261A (ko) 2018-10-22
ZA201804137B (en) 2022-08-31
TN2018000213A1 (en) 2019-10-04
CN114634447A (zh) 2022-06-17
US11471441B2 (en) 2022-10-18
KR20210018530A (ko) 2021-02-17
US20230372298A1 (en) 2023-11-23
ZA202107472B (en) 2023-03-29
NL301262I2 (nl) 2024-04-24
MD3390395T2 (ro) 2021-02-28
CO2018006164A2 (es) 2018-09-20
US10464905B2 (en) 2019-11-05
AU2016373530B2 (en) 2021-01-21
HK1263254A1 (zh) 2020-02-21
US20220062239A1 (en) 2022-03-03
CN114573510A (zh) 2022-06-03
CN114591242A (zh) 2022-06-07
US20180362512A1 (en) 2018-12-20
JP7086140B2 (ja) 2022-06-17
CA3008488A1 (fr) 2017-06-22
KR102215792B1 (ko) 2021-02-16
IL285976A (en) 2021-10-31
IL285976B1 (en) 2023-06-01
AU2021225162A1 (en) 2021-09-30
US10342780B2 (en) 2019-07-09
JP2020172535A (ja) 2020-10-22
CN114621146A (zh) 2022-06-14
CN108473481A (zh) 2018-08-31
US20210093611A1 (en) 2021-04-01
PH12018501268A1 (en) 2019-02-18
RS60982B1 (sr) 2020-11-30
EP3390395B1 (fr) 2020-09-09
ES2828431T3 (es) 2021-05-26
SG11201805044WA (en) 2018-07-30
FIC20240004I1 (fi) 2024-03-01

Similar Documents

Publication Publication Date Title
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
EA202091709A1 (ru) Ингибиторы днк-пк
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MX2020010805A (es) Inhibidores de bcl6.
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
EA202091708A1 (ru) Ингибиторы днк-пк
MX2020002399A (es) Inhibidores del enlace proteína-proteína de wdr5.
MA38284B1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
TN2018000341A1 (en) ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF.
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
PH12021550743A1 (en) Boron containing pde4 inhibitors
MX2015010983A (es) Inhibidores de tirosina-cinasa de bruton.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA42871B1 (fr) Composés utilisés comme inhibiteurs de la tyrosine kinase de bruton (btk)
MA42175B1 (fr) Dérivés de pyrazolopyrimidine comme inhibiteurs de btk pour le traitement du cancer
MA38523A1 (fr) Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma
MA45367B1 (fr) Inhibiteurs de la tyrosine kinase
EA202190690A1 (ru) Борсодержащие ингибиторы pde4